PALLAS : limiting indications for dronedarone treatment of atrial fibrillation.
Doggrell, Sheila & Hancox, Jules (2012) PALLAS : limiting indications for dronedarone treatment of atrial fibrillation. Expert Opinion on Pharmacotherapy, 13(6), pp. 867-871.
Atrial fibrillation increases the risk of stroke. Dronedarone has been shown to reduce the composite of hospitalizations due to cardiovascular events or death, in subjects with intermittent atrial fibrillation or flutter. Recently, dronedarone has been tested in subjects with permanent atrial fibrillation in the PALLAS (permanent atrial fibrillation outcome study using dronedarone on top of standard therapy) trial, and this clinical trial is evaluated in this paper. PALLAS was stopped early as there was an increased incidence of cardiovascular events in the dronedarone group. Dronedarone also increased the rate of hospitalizations in PALLAS. As a result of PALLAS, dronedarone has been contraindicated in permanent atrial fibrillation. The outcomes of PALLAS highlight a discontinuity between dronedarone actions in permanent and intermittent atrial fibrillation. The mechanism(s) underlying the detrimental effects of dronedarone in permanent atrial fibrillation are unknown at present and need to be investigated.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||dronedarone, atrial fibrillation|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500)|
|Divisions:||Current > QUT Faculties and Divisions > Faculty of Health|
|Copyright Owner:||Coyright 2012 2012 Informa UK, Ltd.|
|Copyright Statement:||All rights reserved: reproduction in whole or in part not permitted|
|Deposited On:||05 Nov 2012 00:15|
|Last Modified:||01 Feb 2015 21:25|
Repository Staff Only: item control page